title: [Dynamic study of Bcl-2, Bax, p53, and ACE expression in CD34+ cells of peripheral blood and bone marrow in acute leukemia patients in the course of induction chemotherapy].
abstract: OBJECTIVE
  To determine unbalance in the system of programmed cell death in the cells CD34+ of the bone marrow (BM) and peripheral blood (PB) before and after cytostatic impact in acute leukemia (AL).
  
  
  METHODS
  Flow cytoflowmetry estimated expression of Bcl-2, Bax, p53 and ACE in the cells CD34+ of BM and PB from 10 AL (4 AML and 6 ALL) patients. PB and BM samples were studied before polychemotherapy (PCT) and in the course of induction treatment: on day +8, +21 (blood only), +36 - 38. Control group consisted of 4 BM donors.
  
  
  RESULTS
  The number of CD34+ cells expressing Bcl-2 in AL patients was 46,5 +/- 9,35 % in BM and 39,4 + 10,8 % in PB, in healthy donors - 9 and 32,8 %, respectively. Bax expression in AL patients' cells CD34+ of BM versus this expression in donors was 3 times higher (36,7 +/- 8,1 and 14,8%, respectively), of PC - 2 times lower (40,7 +/- 6,59 and 75,8%, respectively). Expression of p53 in AL patients was 36,8 +/- 9 % in BM and 26 +/- 7,4 % in PB, in donors - 28,2 and 65 %, respectively. ACE expression on the cells CD34+ in AL patients in early disease was 62 +/- 7,57 % in BM and 48 +/- 8,1 % in PB, in donors - 40 and 85 %, respectively. Moreover, there were significant changes in expression of Bcl-2 in BM and Bax, ACE and p53 in PB in the cells CD34+ in AL patients during and after induction PCT.
  
  
  CONCLUSIONS
  The above changes evidence for unbalance of pro- and antiapoptosis proteins of regulators in AL patients. PCT changes profile of expression of these proteins, but not to the level of healthy donors.
authors: E E
authors: EE
authors: Khodunova
authors: E N
authors: EN
authors: Parovichnikova
authors: I V
authors: IV
authors: Gal'tseva
authors: S M
authors: SM
authors: Kulikov
authors: V G
authors: VG
authors: Isaev
authors: V G
authors: VG
authors: Savchenko
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism*; D016022:Case-Control Studies; D005434:Flow Cytometry; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000378:metabolism; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000097:blood / Q000378:metabolism; D012074:Remission Induction; D016159:Tumor Suppressor Protein p53 / Q000097:blood / Q000378:metabolism; D055815:Young Adult; D051028:bcl-2-Associated X Protein / Q000097:blood / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; C494826:BAX protein, human; D014408:Biomarkers, Tumor; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D007703:Peptidyl-Dipeptidase A